Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Novartis building

Novartis boosts cardiovascular pipeline with $1bn Ionis deal

Gains rights to two lipoprotein-targeting drugs currently in early-stage clinical development 

Bayer promotes Robert LaCaze

He becomes EVP of new oncology strategic business unit

- PMLiVE

Novartis launches heart failure social network

Together in HF is the first digital effort of its kind for the condition

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Speaking the language of effective communications

Crafting appropriate communications still requires the fundamentals to be done brilliantly, but increasingly a smarter integrated approach is key, says Claire Gillis

- PMLiVE

Merck & Co’s Dr Daniel Pascheles joins Molekule Consulting

He becomes the biopharma services provider’s CEO

J&J collaborates on consumer health device accelerator

Partners with Shenzhen-based investor firm HAX

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

- PMLiVE

Eisai takes control of weight loss drug Belviq from Arena

Buys global rights to obesity drug in $49m deal to expedite roll-out and boost sales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links